U.S. patients: Denali’s natural history study still enrolling

May 8, 2023

Reminder: Denali Therapeutics is still enrolling patients with Sanfilippo Syndrome Type IIIA for its two-year natural history study.

Denali Therapeutics is developing an enzyme replacement therapy for individuals with Sanfilippo type A. As part of their development program, they are working with another company called Sanguine to run a natural history study.

This study consists of surveys completed by a parent and the collection of blood samples over a two-year period.

This study does not require any travel. A health professional will come to your home to collect blood samples and you will fill out surveys on an electronic device provided to you for the duration of the study.

Enrollment remains open for the study at this time.

In addition to the flyer below, you can go to this link to find out more and sign up.

If you have any questions, feel free to reach out to us at Contact@CureSanfilippoFoundation.org

Related Posts